The Great Alzheimer’s Trap: Why Science Stopped Looking for Real Answers

Science is the belief in the ignorance of experts — Richard Feynman

The Midwestern Doctor’s essay, The Great Alzheimer’s Scam and the Proven Cures They Don’t Want You to Know About, has been shared everywhere, usually with two reactions: outrage from families who feel betrayed, and dismissal from professionals who say it’s conspiracy theory. The truth lies somewhere between those extremes.

The article is right that something has gone badly wrong in Alzheimer’s research — but not because there’s a simple cure being hidden. The deeper tragedy is that science itself has been captured by money, bureaucracy, and fear of deviation.

The author is correct that Alzheimer’s research has been locked for decades into one grand idea: that sticky proteins called amyloid plaques cause the disease. Billions have been spent trying to remove these plaques, yet most of the drugs have failed. Still, money continues to pour into the same line of work, because that is where the government grants, academic promotions, and drug-company profits all converge.

When Biogen’s drug Aduhelm was approved in 2021, it became a symbol of this system. The company’s own trials showed no clear benefit, yet the U.S. Food and Drug Administration (FDA) licensed it using a regulatory shortcut meant for desperate situations. A later Congressional investigation found “inappropriate collaboration” between Biogen and the FDA. That is not conspiracy theory; it is documented fact.

So the Midwestern Doctor is right to attack corruption and groupthink. When a field depends on a single profitable theory, everyone learns to protect it.

The title promises “proven cures” that are being suppressed. That is misleading. There are lifestyle programmes claiming to reverse Alzheimer’s — such as those designed by Dr Dale Bredesen — but the evidence so far is weak. Most studies are tiny, uncontrolled, and measure improvement in ways that are easy to bias. They show possibility, not proof.

At the same time, it is unfair to claim that all new drugs are scams. The newer treatment Lecanemab (Leqembi) really does seem to slow cognitive decline a little, though it can cause dangerous brain swelling. It is far from a miracle and ruinously expensive, yet it is something.

One side oversells chemicals; the other oversells “natural” fixes. Neither tells the full story.

The deeper problem is structural. Science now follows the path of least financial resistance.

The business of certainty Drug companies fund what regulators will approve, and regulators approve what drug companies are already testing. That circular relationship keeps everyone safe — financially, if not scientifically. Once amyloid was declared the official biomarker, every firm had to chase it. Any other idea would take years just to be accepted as valid. Innovation died under paperwork.

Bureaucratic fear Researchers who propose different causes — infection, insulin resistance, or environmental toxins — struggle for grants. Committees prefer familiar words and phrases. This is not deliberate conspiracy but human risk-aversion. Nobody gets fired for following the crowd.

Legal intimidation When independent scientists challenged a company’s Alzheimer’s data in 2021, they were met with lawsuits. Even if those cases were weak, the message was plain: don’t criticise. The same fear spreads in universities, where whistle-blowers are seen as liabilities.

The cost of over-correction After the Aduhelm scandal, the FDA tightened rules so much that only the richest companies can now afford to run trials. That seems prudent, but it means small labs with fresh ideas are priced out before they begin.

This is how science stagnates — not through villainy, but through the weight of its own bureaucracy.

To make progress, we need less politics and more variety. We need this:

Multiple targets: Regulators should accept several biological markers — inflammation, blood flow, metabolism, infection — not just amyloid.
Smaller, faster trials: Public agencies could fund short, open studies to test new ideas cheaply, instead of waiting for billion-dollar companies to act.
Transparency: All industry–government meetings should be recorded, and all trial data published. That protects both patients and honest scientists.
Even-handed discipline: Journals must check every image and dataset, not just those from unfashionable labs. Fraud should be punished wherever it appears.

This is simply the scientific version of a free market — open competition between ideas, not monopolies guarded by red tape.

The Midwestern Doctor performs a public service by exposing how the Alzheimer’s establishment protects itself. His anger is justified; his certainty is not. There are no hidden cures waiting to be unbanned, but there is a captured system that rewards familiar molecules, profitable trials, and endless committees.

Real progress will come only when governments stop picking winners and let ideas fight on merit.

Further Reading

Mainstream and technical sources

Investigations and critiques

Alternative and lifestyle approaches

On capture and scientific freedom